FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W208593668> ?p ?o ?g. }

• W208593668 abstract "Background Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. Antithrombin III (AT III) is an anticoagulant with anti‐inflammatory properties but the efficacy and any harmful effects of AT III supplementation in critically ill patients are unknown. Objectives To assess the benefits and harms of AT III in critically ill patients. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); MEDLINE; EMBASE; Science Citation Index Expanded; International Web of Science; CINAHL; LILACS; and the Chinese Biomedical Literature Database (up to November 2006). We contacted authors and manufacturers in the field. Selection criteria We included all randomized clinical trials, irrespective of blinding or language, that compared AT III with no intervention or placebo in critically ill patients. Data collection and analysis Our primary outcome measure was mortality. We each independently abstracted data and resolved any disagreements by discussion. We presented pooled estimates of the intervention effects on dichotomous outcomes as relative risks (RR) with 95% confidence intervals (CI). We performed subgroup analyses to assess risk of bias, the effect of AT III in different populations (sepsis, trauma, obstetric, and paediatric patients), and the effect of AT III in patients with or without the use of concomitant heparin. We assessed the adequacy of the available number of participants and performed a trial sequential analysis to establish the implications for further research. Main results We included 20 randomized trials with a total of 3458 participants; 13 of these trials had high risk of bias. When we combined all trials, AT III did not statistically significantly reduce overall mortality compared with the control group (RR 0.96, 95% CI 0.89 to 1.03; no heterogeneity between trials). A total of 32 subgroup and sensitivity analyses were carried out. Analyses based on risk of bias, different populations, and the role of adjuvant heparin gave insignificant differences. AT III reduced the multiorgan failure score among survivors in an analysis involving very few patients. AT III increased bleeding events (RR 1.52, 95% CI 1.30 to 1.78). Authors' conclusions AT III cannot be recommended for critically ill patients based on the available evidence. A randomized controlled trial of AT III, without adjuvant heparin, with prespecified inclusion criteria and good bias protection is needed." @default.
• W208593668 created "2016-06-24" @default.
• W208593668 creator A5002058390 @default.
• W208593668 creator A5035047848 @default.
• W208593668 creator A5040905987 @default.
• W208593668 date "2008-07-16" @default.
• W208593668 modified "2023-09-26" @default.
• W208593668 title "Antithrombin III for critically ill patients" @default.
• W208593668 cites W1576352249 @default.
• W208593668 cites W1588026902 @default.
• W208593668 cites W1600041372 @default.
• W208593668 cites W1606979836 @default.
• W208593668 cites W1607813664 @default.
• W208593668 cites W1755665316 @default.
• W208593668 cites W187165820 @default.
• W208593668 cites W1964168896 @default.
• W208593668 cites W1968014497 @default.
• W208593668 cites W1970394345 @default.
• W208593668 cites W1970982032 @default.
• W208593668 cites W1971441597 @default.
• W208593668 cites W1971537896 @default.
• W208593668 cites W1979012632 @default.
• W208593668 cites W1980347291 @default.
• W208593668 cites W1981177870 @default.
• W208593668 cites W1982379437 @default.
• W208593668 cites W1988178206 @default.
• W208593668 cites W1989200494 @default.
• W208593668 cites W1989317042 @default.
• W208593668 cites W1990456302 @default.
• W208593668 cites W1996470340 @default.
• W208593668 cites W1997206071 @default.
• W208593668 cites W2004313871 @default.
• W208593668 cites W2005888993 @default.
• W208593668 cites W2006894744 @default.
• W208593668 cites W2010399673 @default.
• W208593668 cites W2014755540 @default.
• W208593668 cites W2015678328 @default.
• W208593668 cites W2017401577 @default.
• W208593668 cites W2026976322 @default.
• W208593668 cites W2030669625 @default.
• W208593668 cites W2030780661 @default.
• W208593668 cites W2033137912 @default.
• W208593668 cites W2036260951 @default.
• W208593668 cites W2036474812 @default.
• W208593668 cites W2042153013 @default.
• W208593668 cites W2048933053 @default.
• W208593668 cites W2049020632 @default.
• W208593668 cites W2049927822 @default.
• W208593668 cites W2053804518 @default.
• W208593668 cites W2056756157 @default.
• W208593668 cites W2059243750 @default.
• W208593668 cites W2059841871 @default.
• W208593668 cites W2068110779 @default.
• W208593668 cites W2068667014 @default.
• W208593668 cites W2074301109 @default.
• W208593668 cites W2074472139 @default.
• W208593668 cites W2074636483 @default.
• W208593668 cites W2085280114 @default.
• W208593668 cites W2088870170 @default.
• W208593668 cites W2092973141 @default.
• W208593668 cites W2093446780 @default.
• W208593668 cites W2102696978 @default.
• W208593668 cites W2115301416 @default.
• W208593668 cites W2115368188 @default.
• W208593668 cites W2115913948 @default.
• W208593668 cites W2126930838 @default.
• W208593668 cites W2129434923 @default.
• W208593668 cites W2135740385 @default.
• W208593668 cites W2157823046 @default.
• W208593668 cites W2162051878 @default.
• W208593668 cites W2164729929 @default.
• W208593668 cites W2167304859 @default.
• W208593668 cites W2322121630 @default.
• W208593668 cites W2328527018 @default.
• W208593668 cites W2331870538 @default.
• W208593668 cites W38706586 @default.
• W208593668 cites W4242589154 @default.
• W208593668 cites W4256411206 @default.
• W208593668 cites W4321318382 @default.
• W208593668 cites W98363274 @default.
• W208593668 doi "https://doi.org/10.1002/14651858.cd005370.pub2" @default.
• W208593668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18646125" @default.
• W208593668 hasPublicationYear "2008" @default.
• W208593668 type Work @default.
• W208593668 sameAs 208593668 @default.
• W208593668 citedByCount "30" @default.
• W208593668 countsByYear W2085936682012 @default.
• W208593668 countsByYear W2085936682014 @default.
• W208593668 countsByYear W2085936682015 @default.
• W208593668 countsByYear W2085936682016 @default.
• W208593668 countsByYear W2085936682017 @default.
• W208593668 countsByYear W2085936682018 @default.
• W208593668 countsByYear W2085936682019 @default.
• W208593668 countsByYear W2085936682020 @default.
• W208593668 countsByYear W2085936682021 @default.
• W208593668 countsByYear W2085936682022 @default.
• W208593668 crossrefType "reference-entry" @default.
• W208593668 hasAuthorship W208593668A5002058390 @default.
• W208593668 hasAuthorship W208593668A5035047848 @default.
• W208593668 hasAuthorship W208593668A5040905987 @default.

• next